Use of Tocilizumab May Avoid the Need of Invasive Ventilation
Open Access
- 8 September 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Abstract
Coronavirus disease 2019 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Increased pro-inflammatory cytokines including interleukin 6 (IL-6) are associated with severe forms of illnesses. The severe cases of COVID-19 require a high amount of oxygen supplementation and might even require endotracheal intubation with ventilator support. A blockade of inflammatory cascade with the use of tocilizumab has been shown to decrease the need for intubation and ventilator requirement.Keywords
This publication has 16 references indexed in Scilit:
- Rationale and evidence on the use of tocilizumab in COVID-19: a systematic reviewPulmonology, 2021
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19New England Journal of Medicine, 2020
- Tocilizumab for severe COVID-19: a systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2020
- An inflammatory cytokine signature predicts COVID-19 severity and survivalNature Medicine, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences, 2020
- Why tocilizumab could be an effective treatment for severe COVID-19?Journal of Translational Medicine, 2020
- The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patientsInflammation Research, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- A panoramic review of IL-6: Structure, pathophysiological roles and inhibitorsBioorganic & Medicinal Chemistry, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020